OptiKira raises $3.7 million to develop treatments for blindness

Story excerpt provided by Crain’s Cleveland Business.

Written by Chuck Soder.

Investors have injected $3.7 million into a startup company developing treatments for blindness and other diseases caused by progressive cell death.

OptiKira LLC, a spinoff of Shaker Heights-based BioMotiv, will use the money to continue developing drugs that could be used to treat degenerative eye diseases, according to BioMotiv CEO Baiju Shah.

OptiKira, which is based at BioMotiv’s office, eventually aims to develop drugs for other diseases, such as diabetes and ALS (amyotrophic lateral sclerosis).

Click here to read the complete article.

Originally published August 9, 2016.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: